ADX-2191 (intravitreal methotrexate 0.8%)
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Vitreoretinopathy
Conditions
Proliferative Vitreoretinopathy
Trial Timeline
Nov 15, 2019 → Jun 14, 2022
NCT ID
NCT04136366About ADX-2191 (intravitreal methotrexate 0.8%)
ADX-2191 (intravitreal methotrexate 0.8%) is a phase 3 stage product being developed by Aldeyra Therapeutics for Proliferative Vitreoretinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04136366. Target conditions include Proliferative Vitreoretinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04136366 | Phase 3 | Completed |
Competing Products
20 competing products in Proliferative Vitreoretinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| Brolucizumab 6 mg | Novartis | Phase 3 | 77 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Octreotide, 30 mg i.m. LAR formulation | Novartis | Phase 3 | 77 |
| Ranibizumab 0.5 mg | Novartis | Phase 2 | 52 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen (pegaptanib) + Macugen (Pegaptanib) | Pfizer | Pre-clinical | 22 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
Other Products from Aldeyra Therapeutics
Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BIDPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Placebo Comparator + Reproxalap Ophthalmic Solution (0.25%) + Placebo ComparatorPhase 3
69